ArticleJournal of thoracic disease2025
The value of chromosome 8 heteroploid tumor cells in the peripheral blood and pleural effusion in evaluating treatment efficacy and the prognosis of metastatic non-small cell lung cancer patients.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) is a major global health concern, especially in its advanced stages, where patient prognosis is frequently unfavorable. Research has shown that circulating tumor cells (CTCs) can serve as markers of tumor dissemination, and CTCs may influence chemotherapy effectiveness and survival rates in patients with malignant pleural effusion. Moreover, chromosomal abnormalities, particularly chromosome 8 aneuploidy, have significant potential implications for disease progression and the treatment response. The aim of this study is to elucidate the relationships between CTCs, chromosome 8 aneuploidy and the chemotherapy response and survival outcomes of metastatic NSCLC patients. Methods: We examined 26 newly diagnosed NSCLC patients with malignant pleural effusion. Specifically, we employed a combination of separation enrichment (SE) and interphase fluorescence Results: We found that CTCs were present in 92.3% of the patients, and we observed a significant decrease in the aneuploid CTC counts of the patients who exhibited partial responses (PRs) to chemotherapy (P=0.002). Notably, the detection of ≥2 trisomy or tetrasomy CTCs post-treatment was associated with shorter progression-free survival (PFS) (P=0.03). Additionally, the presence of aneuploid tumor cells in pleural effusion was correlated with poorer PFS and overall survival (OS) outcomes (P=0.001 and P=0.002, respectively). Conclusions: The results suggest that CTC counts and their chromosomal features could serve as significant prognostic indicators for predicting treatment responses in NSCLC. Future studies with larger patient cohorts need to be conducted to validate these findings and assess the feasibility of using CTC analyses as routine clinical instruments. This approach could ultimately contribute to the development of personalized treatment plans for the effective management of NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.